Aquestive Therapeutics, Inc.
AQST
$6.54
-$0.15-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -152.89% | -88.55% | -460.83% | -190.59% | -13.74% |
| Total Depreciation and Amortization | -48.03% | -46.33% | -45.99% | -26.14% | -34.05% |
| Total Amortization of Deferred Charges | 50.99% | 135.15% | 443.31% | 4,129.74% | 3,157.47% |
| Total Other Non-Cash Items | 33.56% | 37.61% | 97.30% | 231.31% | 45.52% |
| Change in Net Operating Assets | 72.03% | -68.16% | -86.43% | -205.63% | -144.81% |
| Cash from Operations | -101.32% | -90.68% | -460.49% | -590.28% | -303.39% |
| Capital Expenditure | -45.89% | 74.07% | 84.02% | 84.08% | 78.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -45.89% | 74.07% | 84.02% | 84.08% | 91.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.93% | 99.94% | 99.96% | -210.80% | -210.90% |
| Issuance of Common Stock | -76.63% | -76.32% | 390.88% | 505.70% | 819.26% |
| Repurchase of Common Stock | -10.47% | -1.67% | -9,909.09% | -9,900.00% | -6,314.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.20% | -100.12% | -100.07% | 578.14% | 442.36% |
| Cash from Financing | -77.60% | -76.30% | 2,003.47% | 29,509.49% | 2,015.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.50% | -138.85% | 1,501.76% | 745.18% | 1,322.36% |